Delivery Order SPE2DB22D2009-SPE2DB25FM1SR
- Not listed
- The Defense Logistics Agency awarded a $45,143 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Menveo 1 vial combination vaccine (A-C-Y-W-135) in 0.5ML format. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $12,318.60 to AmerisourceBergen Drug Corp for the supply of Menveo 1 vial combination vaccine (A-C-Y-W-135-DIP) in 0.5mL dosage. This non-competitive delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a time-sensitive pharmaceutical procurement fulfilled from the vendor's location in Conshohocken, Pennsylvania. The order falls under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $13,397.27 on August 12, 2025, for the supply of Menveo 1 Vial-A-C-Y-W-135-DIP 0.5ML, a meningococcal vaccine. This firm fixed price delivery order, with an ultimate completion date of August 13, 2025, carries no set-aside designation and represents a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $7,318.20 delivery order to AmerisourceBergen Drug Corp for Menveo vaccine (1 vial-A-C-Y-W-135-DIP 0.5ML) on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. As a child contract, this delivery order executes under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $14,858.01 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Menveo 1 Vial-A-C-Y-W-135-DIP 0.5ML, a meningococcal vaccine. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 21, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $5,868.13 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Menveo 1 vial (A-C-Y-W-135-DIP) 0.5ML, a meningococcal conjugate vaccine. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work is to be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Menveo 1 vial (A-C-Y-W-135-DIP) 0.5mL vaccine, with a ceiling value of $6,449.00. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $19,943.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Menveo A-C-Y-W vaccine kits (two vials) on September 26, 2025, with an ultimate completion date of September 29, 2025. This delivery order, issued as a non-set-aside competitive award, draws from AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999 and extending through December 2026. The order will be...
- The Defense Logistics Agency awarded a $152,714.53 delivery order to AmerisourceBergen Drug Corp for Menveo 1 Vial A-C-Y-W-135-DIP 0.5ML vaccine products, with an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Menveo vaccine (5-dose vials) with a ceiling value of $33,937.18. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the prime contractor. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025....
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM1SRDelivery Order
The Defense Logistics Agency awarded a $13,157.22 delivery order to AmerisourceBergen Drug Corp for Menveo vaccine (1 vial combination A-C-Y-W-135 diphtheria, 0.5mL) on September 26, 2025, with completion targeted for September 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and identifies AmerisourceBergen's Conshohocken, Pennsylvania location as the place of performance. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a broad range of pharmaceutical products and medical supplies to support Department of Defense and other federal healthcare systems. The company's extensive contract portfolio with DLA reflects its capability to fulfill federal requirements across multiple therapeutic domains, including vaccines, specialty medications, and medical devices. This particular delivery order for Menveo vaccine supports the company's role as a primary vendor in the DLA's pharmaceutical supply chain, which serves military personnel, veterans, and other federal healthcare beneficiaries globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.2k | 9/26/25 |